Skip to main content

Table 2 First-line anticancer treatment according to gene aberration test status

From: A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

Treatment, n (%) Gene aberration
N = 932
Positive Negative Unknown
  EGFRa ALKb ROS1 n = 307 n = 267
  n = 309c n = 48 n = 1
TKI, n = 243 207 (67.0) 20 (41.7)d 1 6 (2.0) 9 (3.4)
 EGFR,e n = 223 205 (66.3) 3 (6.25)d 0 6 (2.0) 9 (3.4)
 ALK,f n = 19 1 (0.3) 17 (35.4) 1 0 0
Chemotherapy,g n = 676 95 (30.7) 27 (56.3) 0 296 (96.4) 258 (96.6)
TKI + Chemotherapy, n = 13 7 (2.3) 1 (2.1) 0 5 (1.6) 0
  1. ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, ROS1 c-ros oncogene 1, TKI tyrosine kinase inhibitor, VEGFR vascular endothelial growth factor receptor
  2. a EGFR gene mutation positive test included all activating mutations in exons 18-21
  3. b ALK tests were determined by fluorescence in situ hybridization, immunohistochemistry, or next-generation sequencing
  4. cOne patient with an EGFR gene mutation was treated with the VEGFR-TKI apatinib
  5. dThree patients with ALK gene fusions had coexisting EGFR gene mutations and were treated with EGFR-TKIs
  6. eEGFR-TKIs were gefitinib, erlotinib, icotinib, epitinib, and allitinib
  7. fALK-TKIs were crizotinib and ceritinib
  8. gChemotherapy included singlet, platinum-doublet, and platinum-doublet plus bevacizumab (triplet) regimens